GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Enterprise Value

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Enterprise Value : €4,567.3 Mil (As of May. 29, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Laboratorios Farmaceuticos Rovi's Enterprise Value is €4,567.3 Mil. Laboratorios Farmaceuticos Rovi's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €179.1 Mil. Therefore, Laboratorios Farmaceuticos Rovi's EV-to-EBIT ratio for today is 25.50.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Laboratorios Farmaceuticos Rovi's Enterprise Value is €4,567.3 Mil. Laboratorios Farmaceuticos Rovi's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €204.2 Mil. Therefore, Laboratorios Farmaceuticos Rovi's EV-to-EBITDA ratio for today is 22.36.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Laboratorios Farmaceuticos Rovi's Enterprise Value is €4,567.3 Mil. Laboratorios Farmaceuticos Rovi's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €779.1 Mil. Therefore, Laboratorios Farmaceuticos Rovi's EV-to-Revenue ratio for today is 5.86.


Laboratorios Farmaceuticos Rovi Enterprise Value Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Enterprise Value Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,368.57 2,119.84 4,019.51 1,837.09 3,163.78

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,944.45 2,173.90 2,732.36 3,163.78 4,151.42

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Enterprise Value

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Enterprise Value falls into.



Laboratorios Farmaceuticos Rovi Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Laboratorios Farmaceuticos Rovi's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Laboratorios Farmaceuticos Rovi's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Laboratorios Farmaceuticos Rovi's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4567.347/179.085
=25.50

Laboratorios Farmaceuticos Rovi's current Enterprise Value is €4,567.3 Mil.
Laboratorios Farmaceuticos Rovi's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €179.1 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Laboratorios Farmaceuticos Rovi's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=4567.347/204.226
=22.36

Laboratorios Farmaceuticos Rovi's current Enterprise Value is €4,567.3 Mil.
Laboratorios Farmaceuticos Rovi's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €204.2 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Laboratorios Farmaceuticos Rovi's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4567.347/779.054
=5.86

Laboratorios Farmaceuticos Rovi's current Enterprise Value is €4,567.3 Mil.
Laboratorios Farmaceuticos Rovi's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €779.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorios Farmaceuticos Rovi Enterprise Value Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.